Advanced NSCLC Patients With EGFR T790M Harboring TP53 R273C or KRAS G12V Cannot Benefit From Osimertinib Based on a Clinical Multicentre Study by Tissue and Liquid Biopsy.
Fu Y, Wang A, Zhou J, Feng W, Shi M, Xu X, Zhao H, Cai L, Feng J, Lv X, Zhang X, Xu W, Zhang Z, Ma G, Wang J, Zhou T, Zhao D, Fang H, Liu Z, Huang JA.
Fu Y, et al. Among authors: wang j, wang a.
Front Oncol. 2021 Feb 24;11:621992. doi: 10.3389/fonc.2021.621992. eCollection 2021.
Front Oncol. 2021.
PMID: 33718183
Free PMC article.